These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34222740)

  • 1. Letter to the Editor: Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use.
    Ng AC
    Hepatol Commun; 2021 Oct; 5(10):1801-1802. PubMed ID: 34222740
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: Reply to Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use.
    Efe C; Wahlin S
    Hepatol Commun; 2022 Nov; 6(11):3272. PubMed ID: 34558846
    [No Abstract]   [Full Text] [Related]  

  • 3. Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis.
    Wahlin S; Efe C
    J Hepatol; 2021 Mar; 74(3):753-755. PubMed ID: 33309114
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
    Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis".
    Lohse AW; Sebode M; Vesterhus M
    J Hepatol; 2021 Mar; 74(3):755-756. PubMed ID: 33309116
    [No Abstract]   [Full Text] [Related]  

  • 6. Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19.
    Pearson MM; Limaye AP; Biggins SW
    Gastroenterology; 2021 Mar; 160(4):1012-1013. PubMed ID: 33387518
    [No Abstract]   [Full Text] [Related]  

  • 7. Practical Consideration for Drug Monitoring of Tacrolimus in Liver Transplantation Recipients with SARS-CoV-2 Infection.
    Joshi T; Rana A; Vierling JM; Kanwal F; Goss JA; Cholankeril G
    Liver Transpl; 2022 Jan; 28(1):127-130. PubMed ID: 34416083
    [No Abstract]   [Full Text] [Related]  

  • 8. Topical steroids and topical tacrolimus appear safe regarding the COVID-19 epidemic.
    Souaid K; Klejtman T; Kramkimel N; Isnard C; Dupin N; Aractingi S
    Ann Dermatol Venereol; 2021 Jun; 148(2):122-123. PubMed ID: 33551212
    [No Abstract]   [Full Text] [Related]  

  • 9. Tacrolimus Use and COVID-19 Infection in Patients After Solid Organ Transplantation.
    Yin S; Wang X; Song T
    Gastroenterology; 2021 Aug; 161(2):728-730.e1. PubMed ID: 33539863
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter to the editor: "Autoimmune hepatitis after COVID-19 vaccination".
    Mungmunpuntipantip R; Wiwanitkit V
    Hepatology; 2022 Mar; 75(3):756. PubMed ID: 34797931
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter to the editor: Exacerbation of autoimmune hepatitis after COVID-19 vaccination.
    Cao Z; Gui H; Sheng Z; Xin H; Xie Q
    Hepatology; 2022 Mar; 75(3):757-759. PubMed ID: 34862637
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis.
    Efe C; Lammert C; Taşçılar K; Dhanasekaran R; Ebik B; Higuera-de la Tijera F; Calışkan AR; Peralta M; Gerussi A; Massoumi H; Catana AM; Purnak T; Rigamonti C; Aldana AJG; Khakoo N; Nazal L; Frager S; Demir N; Irak K; Melekoğlu-Ellik Z; Kacmaz H; Balaban Y; Atay K; Eren F; Alvares-da-Silva MR; Cristoferi L; Urzua Á; Eşkazan T; Magro B; Snijders R; Barutçu S; Lytvyak E; Zazueta GM; Demirezer-Bolat A; Aydın M; Heurgue-Berlot A; De Martin E; Ekin N; Yıldırım S; Yavuz A; Bıyık M; Narro GC; Kıyıcı M; Akyıldız M; Kahramanoğlu-Aksoy E; Vincent M; Carr RM; Günşar F; Reyes EC; Harputluoğlu M; Aloman C; Gatselis NK; Üstündağ Y; Brahm J; Vargas NCE; Güzelbulut F; Garcia SR; Aguirre J; Anders M; Ratusnu N; Hatemi I; Mendizabal M; Floreani A; Fagiuoli S; Silva M; Idilman R; Satapathy SK; Silveira M; Drenth JPH; Dalekos GN; N Assis D; Björnsson E; Boyer JL; Yoshida EM; Invernizzi P; Levy C; Montano-Loza AJ; Schiano TD; Ridruejo E; Wahlin S
    Liver Int; 2022 Mar; 42(3):607-614. PubMed ID: 34846800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations?
    Abdollahi M; Ekrami NK; Ghojazadeh M; Boezen HM; Somi M; Alizadeh BZ
    World J Gastroenterol; 2020 Oct; 26(38):5896-5910. PubMed ID: 33132643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity?
    Ghielmetti M; Schaufelberger HD; Mieli-Vergani G; Cerny A; Dayer E; Vergani D; Terziroli Beretta-Piccoli B
    J Autoimmun; 2021 Sep; 123():102706. PubMed ID: 34293683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination: Need for population-based epidemiological study.
    Suzuki Y; Kakisaka K; Takikawa Y
    Hepatology; 2022 Mar; 75(3):759-760. PubMed ID: 34904265
    [No Abstract]   [Full Text] [Related]  

  • 16. Autoimmune Hepatitis Following Vaccination for SARS-CoV-2 in Korea: Coincidence or Autoimmunity?
    Kang SH; Kim MY; Cho MY; Baik SK
    J Korean Med Sci; 2022 Apr; 37(15):e116. PubMed ID: 35437965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of tacrolimus in refractory autoimmune hepatitis in children and adults: a single center experience.
    Al Taii H; Hanouneh MA; Hanouneh I; Lopez R; Zein N; Alkhouri N
    Scand J Gastroenterol; 2017 Feb; 52(2):157-158. PubMed ID: 27633047
    [No Abstract]   [Full Text] [Related]  

  • 18. Autoimmune hepatitis after COVID-19 vaccination.
    Zheng H; Zhang T; Xu Y; Lu X; Sang X
    Front Immunol; 2022; 13():1035073. PubMed ID: 36505482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is immunosuppression truly associated with worse outcomes in autoimmune hepatitis patients with COVID-19?
    Terziroli Beretta-Piccoli B; Lleo A
    Liver Int; 2022 Feb; 42(2):274-276. PubMed ID: 35092335
    [No Abstract]   [Full Text] [Related]  

  • 20. Autoimmune hepatitis triggered by COVID-19: A report of two cases.
    Kabaçam G; Wahlin S; Efe C
    Liver Int; 2021 Oct; 41(10):2527-2528. PubMed ID: 34478591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.